Camille Pope is the Chief Medical Lead at Acclinate, helping pharmaceutical companies and healthcare organizations access and engage communities of color so research is more inclusive. She'd previously worked for several large pharmaceutical companies in both field medical and medical affairs leadership roles. We discuss the importance of diversity in clinical trials, the new FDA guidance, the impacts that a lack of trial diversity can have when presenting information to patients and provide... Pharma Sessions is hosted by Jonathan Kaskey Follow along on LinkedIn: https://www.linkedin.com/in/jonkaskey/ Or join the Pharma Sessions Substack: www.pharmasessions.substack.com
Audio and video play straight from the show's own hosting. PodSubs stores and serves no media.
Transcript
From the show. Tap a time to play from there.
SPEAKER_01In April 2022, there was a draft guidance that came out from the FPA that basically said, Hey, you know, pharmaceutical companies, you need to start really looking at this in a serious way. You need to start submitting diversity plans prior to your pivotal studies even kicking off. You need to be thinking about this early. It's, you know, kind of like no longer an afterthought, and it's no longer just a nice to have. You need to make a concerted effort to um study your drugs and populations that reflect the real world populations that are going to be, you know, using the drugs once they're approved.
SPEAKER_00Hello, hello. This is Jonathan Kaske, and you're listening to Pharma Sessions, a podcast for pharma professionals to talk about all things related to launching a product with excellence. I had a fantastic conversation with Camille Pope about increasing clinical trial diversity. As you probably know, in the 2023 Omnibus Spending Bill enacted in January, there's a requirement for diversity action plans for clinical trials. So how to do adjust.
SPEAKER_00Camille has incredible insight and experience. She has a long and successful career in medical affairs, and she's now the chief medical lead at Acclinate, helping pharma companies and healthcare organizations access and engage communities of color so research is more inclusive. So let's dive right in. Hi Camille, how are you?
SPEAKER_01Hi, John. How are you?
SPEAKER_00I'm great. So let's just get started here. So you're at Accoldate, but you weren't always telling tell me how you how you got to this point and what you were doing before.
SPEAKER_01Okay. My entire career, or I'll I guess I'll give you a brief background of uh my career. So I am a pharma D, graduated from Florida Inham University College of Pharmacy. And right after pharmacy school, completed a pharma D, a pharmaceutical industry, uh pharmaceutical industry fellowship with the Ruckers uh Fellowship uh program, which most folks are familiar with, in conjunction with Bristol Meyer Squibb.
SPEAKER_01And so that fellowship was in medical affairs. And I have pretty much stayed in medical affairs my entire industry career. So I've worked at several different companies in several different roles, but they've primarily been in medical affairs the entire time. So after I finished my fellowship at Bristol Myers Squib, I went on to work at a small biotech called Abraxis, still in medical affairs, this time focused in like scientific communications and publications.
SPEAKER_01So stayed in a headquarters type of role. And then after uh leaving Abraxis, I became a medical science liaison. And I thought that was going to be like my end-all, be all career role. I was going to retire as like a, you know, executive principal medical science liaison or something like that. So I worked at several, uh, a couple of different companies as a medical science liaison. My longest time as an MSL was spent at AbV. Interesting story there. When I joined AB, it was not AbV, it was Abbott.
SPEAKER_01So I was there when AB spun off, when Abbott spun off AB into this new company that focused on, you know, the the uh pharmaceutical products versus all of the other, you know, business entities that Abbott had at the time. Um and so I was in MSOL at V for maybe six, six, almost seven years, something, something like that. Um, and I was in the field focused on HIV and hepatitis C. And my territory was the DC metro area, along with um Virginia, West Virginia.
SPEAKER_01Sometimes I had New Jersey and Pennsylvania under my belt too, depending on the ebbs and flows of the team. Um, and after being in the field for a while, I realized that I missed, I missed the strategy setting and the strategy development part of medical affairs, which is what I had done earlier in my career and what I had done in my fellowship. And so I decided that I wanted to leave the MSL role, um, still taking like all of that great knowledge that I had learned in the field and all of that great experience being like the face of a company in that type of position, but take it in-house back into a medical strategy type of position.
SPEAKER_01So that's how I ended up at AstraZeneca. Um, and I was at AstraZeneca in the Washington, DC area for about five years. And again, another therapeutic area shift. I was in oncology. I had done oncology very early on in my career and then went back to it when I uh when I started at AZ. And so at AZ, I was a medical director slash medical lead. The the titles kind of changed while I was there, but ultimately I was um a director for like medical affairs and medical strategy for several different tumor types, mainly prostate cancer, but I also had responsibility for some other tumor types along those five years as well, including breast, gastric, pancreatic cancer.
SPEAKER_01I think those were the main ones. And so then how did I end up at Aquinate? Well, I it was especially in my, certainly in my MSO role, but definitely in my like medical director and medical lead role, where again, you're thinking about strategically, how do you communicate the data to the people who need need it the most to make decisions, right? To healthcare providers, to patients. I always say medical affairs is like the make it make sense function within industry.
SPEAKER_01Like we take all that data and we go, okay, what does it mean? Like, all right, doc, all right, pharmacist, like how do you take this and and really assess the primary endpoint and of, you know, within the study and whether or not the, you know, the study met the primary endpoint and then use the drug in your pay or prescribe the drug in your patients? How do you monitor for safety events that might occur? Like, that's what medical affairs is responsible for is communicating that type of information so that folks can make those decisions about the drugs that are being prescribed.
SPEAKER_01And I found myself always working in these disease areas like HIV, hepatitis C, prostate cancer, breast cancer, where, you know, people who look like me, I'm a black woman, um, where my, you know, family, black men and women in the US are certainly disproportionately impacted in negative ways by these disease areas that I'm working in. Yet the data, the clinical trials that I am, you know, helping to be part of in my roles, when I'm looking at the demographics, I'm not represented.
SPEAKER_01Like neither, neither are people who look like my dad or my brother. Like we there weren't uh large representations or representations reflective of the real world in terms of race and ethnicity in the clinical trials. And I remember even being in a situation where I was presenting data to a patient advocacy, uh to a group of uh uh patient advocates in one of my roles. Uh and one of the leaders of the patient advocacy organization was like, okay, the data are great, the study is positive, but you know, the people who are part of my advocacy group and who have this disease and are looking for you know guidance, they're not represented here.
SPEAKER_01Like, how many black people did you have in the clinical trial?
SPEAKER_00And unfortunately, like was that data captured at that time where you could answer that, or was it it?
SPEAKER_01So it was there. We had, yeah, we and the data was captured, right? But um, it wasn't necessarily reported in the journal publication or in the Congress presentation. It was like in the prescribing information because you do have to usually it's in the prescribing information if anybody really wants to know, but like what patient app, you know, like is reading the 20-page USPI, right? Like it's usually in there in the clinical trial section where you're talking about the patient population for every study.
SPEAKER_01It'll give a breakdown. And so yeah, it was in the PI, but it was like one line in this very large PI. And so it waited was not in the slide deck that I was presenting to this group because the slide deck I was presenting, I think, was based off of like a Congress presentation or a journal publication. And so, yeah, he kind of raised the red flag and was like, Well, you know, you're not presenting it. Where is it? And how many, how many black people were in the study? And so, you know, I I went back, I maybe even during the call, I pulled it up in the PI and I looked and it was a very, very, very low number for a disease that clearly disproportionately like impacts black people.
SPEAKER_01And I he was just like, Well, your study isn't representative, the data are great, but I don't know if it's gonna work, if this drug is gonna work the same for the patients who are, you know, members of my who are part of my patient advocacy group or who follow me. And I was also hearing the same thing from key opinion leaders who were, you know, maybe treating patients um who are primarily from those communities. And I was like, you know, you're right. I can't, I can't disagree with you here.
SPEAKER_00Because you've got this data that is not putting the company that you're representing it in like a good, a good light, but you're you're representing you're representing that company, but then you're hearing from your constituent that because there's no diversity in the trial or not enough diversity in the trial, it actually makes him look with skepticism at at the whole thing. So then is that like is that then something you can take back to your employer and be like, hey, it's actually in your best interest to fix this.
SPEAKER_01Yes.
SPEAKER_00Or looking at you with a side eye.
SPEAKER_01Yeah. So this is what I did. And those for it's exactly what I did. Again, those who worked with me in previous companies can probably attest to this. Like, I did kind of become this squeaky wheel, is what I like to say in a great way, in a good way, because this was before. So now in 2022, in April of 2022, there was a draft guidance that came out from the FPA that basically said, hey, you know, pharmaceutical companies, you need to start really looking at this in a serious way. You need to start submitting diversity plans prior to your pivotal studies even kicking off.
SPEAKER_01You need to be thinking about this early. It's, you know, kind of like no longer an afterthought, and it's no longer just a nice to have. You need to make a concerted effort to study your drugs and populations that reflect the real world populations that are going to be, you know, using the drugs once they're approved. And then that was April 2022. And then there was a law that came out, the um and the like F I forget the full name of it. I just call it the omnibus bill. Um, it was a big bill that had a whole bunch of stuff in it, but there was a specific section in the uh that that got passed in terms of the legislation that put teeth behind that FDA draft guidance um and saying, like, no, by law now FDA has to mandate this.
SPEAKER_01And so the experiences I was having though in presenting clinical data to KOLs and to these patient advocacy groups, like that happened before the FDA draft guidance and this law came out. And so it was even before that that within the companies that I was um I was working, I kind of became the squeaky wheel saying, hey guys, we're we we need to do better by patients. How can we think differently about who we are engaging when it comes to our clinical trials uh, you know, at the patient level?
SPEAKER_01What institutions are we selecting to be part of our clinical trials, where those institutions are located? You know, are we always just picking the same big academic research centers because they quote unquote perform well? Are we thinking about community clinics, upskilling community clinics, maybe connecting community clinics to those academic research centers so that even if they don't have the infrastructure to run a clinical trial, they could be connected to the research center that we have selected to be the clinical trial.
SPEAKER_01Like, how are we thinking about this? And so, yeah, I brought that those questions and that type of thinking to you know, the global medical affairs and the US medical affairs and the clinical development teams for the companies that I I worked for.
SPEAKER_00So at this time, you're you have a fairly big strategic role as a medical director or medical lead for one or multiple tumor types, and then you've got all the associated, you know, stuff that you have to do for your job with that. And did you uh did you do this as part of that job, or did you do this as additional workout outside of it? How did you how did you look at it? What was your mindset? This episode is sponsored by instructor meetings.
SPEAKER_00Check it out at www.structured meetings.com.
SPEAKER_01It was a little bit of both. I mean, I I knew from a business perspective it was important. Right? Like it was it was it was gonna be important to the company at the end of the day. If we are to try, if we're putting patience first, then it needed to be a business imperative. And so I, you know, baked it into my role. But it required me to do so much more uh like above and beyond my day-to-day that it it like, yes, it was part of my role, but it required a lot more than my day-to-day role.
SPEAKER_01Yeah, typically required.
SPEAKER_00And I, you know, I was okay with that. You do you feel like you were out there kind of on you on your own? Were people receptive? Were did you get support? Like, how did how did you manage all of that?
SPEAKER_01I definitely was not on my own. And I will give uh, you know, shout outs to my former companies because they were like, you know, Camille's on a mission. So, and um, you know, and we had um work streams that were already starting to brew, then up in different therapeutic areas and different parts of the company. And so I was like, oh, okay, you know, I'll be part of this, you know, clinical trial diversity working group, and I'll lead specific initiatives within this working group with others who are like-minded and who also know that this is not, you know, yes, it's altruistic and it's the right thing to do for patients, but it's also a business imperative.
SPEAKER_01So there was a lot of support in trying to figure out how to do things better. You know, we came up with projects. I know there was one project where I, you know, I went a particular study for which I was the medical lead. I was like, well, hey, you know, it's already read out. I've already had the data read out, it's done. Um, but you know, if we are gonna have future phase three studies and we want to do better, we should go back to the investigators who were part of that first phase three trial and ask them, like, what are some of the um experiences you had trying to enroll Black people in this particular study?
SPEAKER_01What are some of the barriers that you experience when it comes to historically underrepresented populations and you know, engaging with them? Are there other sites besides yours in the area that we should be considering? Do you have ideas and tips for us? And so I worked with a subgroup within my work stream so I could do this survey. And we, you know, came up with this information or will these insights from these PIs, we already have relationships with them because they were the PIs for the first phase three study.
SPEAKER_01And then we reported that information like back to the clinical development team, back to the medical affairs team, so that for future trials, we could be thinking about this insight and this feedback when we did site selection, when we wrote the, you know, the publication, making sure we're including that information in there for transparency, the feasibility questions that we asked. So that's the type of work that we were doing. And there was a team of several teams of people trying to, you know, uh work through this problem.
SPEAKER_00Yeah, it's so cool because I think medical affairs is like master communicators, right? And it's like they take active listening to the utmost degree where it's like, we're not just gonna active listening, we're gonna like bring in a bunch of KOLs and sit with them for two days and and have these discussions, and then we're gonna marry that with the survey data, and then we're gonna figure out how that needs to be communicated and what way to get the results we want in the field of your medicine. And what you're describing almost sounds like you're doing the same thing, but instead of it's about the medicine, it's about clinical trial diversity.
SPEAKER_01Exactly right. Like that's totally true. And we had to come up with the um for our work stream, like a plan for all of the different things that we wanted to do. So, I mean, I was just part like kind of co-leading that project, but there were several different projects. But you know, you have to have, I didn't need budget for the survey, but there were some things that we needed budget for. And so typically, medical affairs teams, everybody who's ever worked in medical affairs know you have to have a plan. You got to create a medical affairs plan for the year, maybe over a two-year period.
SPEAKER_01And you know, you have your strategic priorities and your objectives and the tactics and then the budget. And so um, on our work stream, it was just like, well, why don't the same way we would create a, you know, a therapeutic area level medical affairs plan, let's use that same template, same format, same way of thinking, and create something like this for our clinical trial diversity work stream. So, you know, you're exactly right. It there are so many like common threads in like how you do things. That that's literally what we did.
SPEAKER_01And that's what we used to make the case for the stuff that did need a budget. That's what we used to make the case to like our leadership team to say, okay, like here's the strategic pillar, here's the objective, here are the tactics that we are proposing to help us reach this end goal, and this is how much money we're going to need. And because it was in the same format as what they had seen before for like the therapeutic area medical affairs plan, it wasn't so difficult to like uh for the leadership team to connect the dots and say, oh, okay, this makes sense.
SPEAKER_01We'll we'll give you, you know, however many thousands. I don't remember how much we were asking for. You know, um, so yeah, there's a common thread. And um right.
SPEAKER_00Well, I think it's cool too, because I mean, just the the people that have been listening to this podcast are typically medical affairs people. And it's like you already have you you have the skills. Um, and you know how to I feel like communication is a superpower and medical affairs people are great at that. Um, can I ask a question about like the makeup, the diversity makeup really of people? And you don't have to answer this specifically about this company, but like, you know, in some ways, Metaffares, I don't know, it it it has there's some areas, some types of people that seem to be underrepresented in in medical affairs, right?
SPEAKER_00How do you see the diversity of the people actually doing the work in Med Affairs or in clinical as like impacting why this is a problem to begin with, or you know, how much how much momentum you can get to try to try to fix diversity in clinical trials, for example?
SPEAKER_01Yeah, it's very important. Workforce workforce diversity is really important because it's, you know, when you have diversity of thought, diversity of experiences, diversity of backgrounds, and you bring that to the table, there are aspects of clinical trial design, site selection, how you communicate with healthcare providers, how you communicate with different patients. There are aspects of that that, like, if you've never experienced certain things, you aren't even thinking about like, oh, this might be offensive, or oh, it, you know, thinking of different social determinants of health and the environment in which the patient populations were trying to reach where they live, how that might impact their ability to get to a clinical trial site.
SPEAKER_01Like if you, if that's not your lived experience or the lived experience of somebody else you know close to you, you're not even thinking about that when you're creating the study protocol or when you're creating the slide deck to present to all the healthcare providers, right? So when you have that diversity of experiences and thinking, uh racial, ethnic background, all of that in the room to provide input, then it helps you come up with a more relevant and better product, whatever that might be, whether it's a slide deck, whether it's a study protocol, a trial design, or something like that.
SPEAKER_00Yeah, it's interesting. So some of the work that I did at a previous company was we kind of work to involve patients in uh clinical trial protocol design. And it was really interesting because you'd be there's these terms used in the pharma like informed consent, and patients are like, what the heck is informed consent? Or like, but then even really basic stuff like, do you want to stay at the hospital or do you want to stay at a hotel near the hospital? Well, if you have an infant that's been diagnosed with a rare disease, like that might actually matter a lot.
SPEAKER_00Or if you're trying to do, I don't know, if if it's requiring you to come to the clinical site every day at you know, two o'clock in the afternoon, that might not be doable. But if you did it after working hours, maybe it would be. I don't know. But it just seems like there's it to me, it's I'm like so impressed whenever somebody successfully manages a trial because there's so many things that can go wrong, right? Um, down at the very end. And even like when we would work on recruiting, as Actually, I'm actually interested in your opinion on this, but like, do you usually when I was working on recruiting, this is now five, seven years ago or so?
SPEAKER_00It seemed like really what it came down to was like, how likely are you gonna be able to fill the amount of patients that we need and how much is it gonna cost? Do you those conversations where people started asking you about like, hey, does your trial population look like me, look like the people that I represent? Are those conversations always happening? Or has there been kind of this momentum building over a period of time? When did people ask that?
SPEAKER_01Um, you mean from like patients who are being offered clinical trials?
SPEAKER_00Or well, I'm thinking more like the story that you told about working with, I guess it was a patient advocacy leader, um, who who raised that concern?
SPEAKER_01Mm-hmm. Well, I I think it depends on who you're asking. Again, this all kind of is like a different pieces of the puzzle. Who are you asking to participate in clinical trials? Number one, a lot of times those who have been historically underrepresented aren't even being asked to participate in clinical trials. So they wouldn't even, they they don't even have an option to ask if the people look like me because the study isn't being offered. The patient advocacy group that I was referring to was actually one specifically for like black patients who had that disease, um, which is, you know, a lot of times in the patient advocacy groups, you don't have the diversity uh right of the actual real world population.
SPEAKER_01So it it kind of goes to that. I will say, um, I'll speak to my current role because that's actually what we were trying to get to, right? So I actually ended up leaving um my last role because, like you asked me, was it um did it feel, did it feel like a job on top of a job? And while, yeah, I was able to integrate a lot of aspects of the clinical child diversity work and also the workforce diversity work that I was doing there into my position, I realized I wanted to do it more fully. I was like, I want to do this like full time.
SPEAKER_01And so that's how I ended up at Acclinate, which is, you know, a small, we call ourselves an upstart, upstart organization that works with many pharmaceutical companies and many healthcare organizations to figure out how do you do this better? How do you engage communities of color that you have not historically engaged in the past and make your research more inclusive through that engagement? How do you measure that? How do you take folks from being totally unwilling to participate to at least being willing to consider a clinical trial?
SPEAKER_01And that goes to the answer of your question now is I think the more that we educate patients who have been historically underrepresented or maybe not asked to participate in a clinical trial because of healthcare bias, people thinking, oh, you know, that person, that type of population doesn't want to do this anyway. They don't have the support. They historical atrocities are gonna say no, right? How do we give those people a voice? And that's what I do in my current role at Acclinate. At least that's one of the things that I do, is give people uh a voice in sharing their stories, but also educate around clinical trials, clinical research, the process, demystify it, help people understand that like clinical trials are a treatment option, just like the approved drugs that are out there being offered to you.
SPEAKER_01You can ask, are there clinical trial options available? Right? You're ask your healthcare provider that. But our goal is to like at acclimate, have folks now included. Now is your time to be included in research, to not be scared, um, because a lot of people have fear. And some of those things you're not going to be able to, you know, take away, but at least you can help educate and bring awareness so that folks can make informed decisions around uh clinical trial participation, whether they say yes or no.
SPEAKER_01And that's what we're we're here to do.
SPEAKER_00Yeah. And I mean, the way you're describing it is education, right? You're not trying to convince them to do it, you're trying to say this is this is an option. There are plus pros and minuses. There's always there's risks involved, but there's also potential benefit that shouldn't, you know, you should be aware of. Um so how much of that do you think is pharma's role versus people outside of pharma, whether it's government or other other institutions to educate people on how this whole system works because it's really complicated.
SPEAKER_01Yeah, well, as you know, we it takes a village. That's what we say in our in our community, it takes a village. So yeah, it's it it's pharma certainly has a big role, right? But pharmaceutical companies aren't going to be able to do it on their own. And I I love, I feel like industry is really starting to realize that. And it's okay. Like, you know, pharmaceutical companies are here to discover and develop drugs, right? Community engagement might not be the, you know, your strongest, I don't know, the strongest thing that you're able to do.
SPEAKER_01But if you're willing to partner with a company that can help you fill the gap, then awesome. Government plays a role in that, you know, they again can put teeth behind, create guidances and laws and put teeth behind it and kind of light a fire under folks who may not think it's important and help them realize how important it is. So it takes a village. I think it's everyone's everyone's responsibility.
SPEAKER_00One of my dad's sayings is a rule without consequences is a suggestion, right? So exactly. And I sort of feel the same way about like, oh, this is a priority without budget, right? Um, and it sounds like um that's a great one. So are yeah. Um are these are there typically like the companies that are working with you, are they typically working out of say their you know, their standard budget? Are there certain allocations to kind of get it depends?
SPEAKER_01It depends. It depends. There are some companies who have been doing this for a long time and trying to figure this out and get it right for a long time. So they have maybe a separate team or a separate budget that is focused on clinical child diversity, and it's you know, beyond a work stream, it's actually like FTE. There's a whole group of people who are employed to do this. Other companies, they're just starting to figure it out, and that's okay. They're like, oh my gosh, diversity plans. This is new, it's required. How do we how do we figure this out? Right. And so they're assigning people within therapeutic areas to help figure out how do we do it and how do we bake this into our budget?
SPEAKER_01Where do we find budget? Do we need a separate budget? I think the most important thing is like whatever, whatever company you're at, start, you know, start. And to start thinking about this early, know that it's gonna take money and time, right? You can't just drop into a community you've never been into in before and and say, hey, I want you to be in a clinical trial and think people are gonna come running. It's not gonna happen that way. You've got to put time to build trust. It takes time to build trust. So yeah, and a lot budget for that.
SPEAKER_01So, yes, some teams have a separate team and a separate budget. Some um have the budget and the team baked into the therapeutic area. Some are figuring out, oh my gosh, how much is this gonna cost? And where do we get the budget? Like everybody is at a different stage. But the cool thing is that you're seeing a lot of companies at least just say, we got to start and it's the right thing to do.
SPEAKER_00And it's also nice because it it does build on itself where it's like, well, once that one, you know, person, that one doctor's office or hospital that wasn't involved in clinical trials before now is, then you know, if Lily does it and then Pfizer comes back to them, they'll be that much, you know, that much further along. Um this is this is really, really cool. And our last uh minute or two, and I only asked this because I heard you on another podcast, and I I heard like the the pride that you had for for Famio and you're almost you want to give like anything you want to say about where people should be where people should be looking for their recruiting, and if you know anything.
SPEAKER_00Oh god.
SPEAKER_01Well, that's a great question because it goes back to workforce diversity, right? So I mean the talent is out there. I went to Florida AM University, I always say it's like the best historically black college university out there, but there are tons of HBCUs, and even outside of HBCUs, there's tons of quote unquote diverse talent, but they may not, people don't always know about these opportunities or have, you know, access to opportunity. And so, as companies, you have to sometimes create that pathway and be very intentional about seeking out the diverse workforce and the diverse talent that you need to bring into your organization to make it whole.
SPEAKER_01And so, you know, I always shout out AstraZeneca. I started like uh this work stream at AZ focused on um inclusive uh talent and recruitment. And I had a whole crew of volunteers that like signed up with me. And we had these initiatives and we got this budget done where we started like fellowships with in a local HBCU to bring in postdoc farm bees and PhDs to get these experiences that they may not have gotten before. And the most rewarding thing is like, even though I've left AZ now to see like the fellow that I brought in, like sleep working at AZ.
SPEAKER_01And I'm like, this is the return on investment. This is exactly what was supposed to happen. Same thing with scholarships that um we provided and seeing those students who were awarded those scholarships are now graduating and they have industry fellowships. And it's like we're creating opportunities for people, and that's what's important. So yeah, go fam you.
SPEAKER_00Thank you, Camille.
SPEAKER_01Thanks, John.
SPEAKER_00Thanks for listening to PharmaSessions. Subscribe for free on Substack at pharmacessions.substack.com for all episodes and exclusive content. This episode is sponsored by structured meetings. For listeners who don't know my background, I'm a huge fan of asynchronous adboards. I used to work for the leading provider of async adboards, and not to brag, but my clients attend more events than anyone else's. I've literally led thousands from the vendor side, so I can humbly claim some expertise.
SPEAKER_00One of the questions I used to get all the time was, can we just do this in teams? And the answer back then was not really. Teams out of the box is clunky and not fit for purpose. Structured meetings change that by creating an MS Teams app that lets you have these discussions in a really smart way in your own teams instance. It changes teams just enough to check all the boxes for what's needed for great ad boards. And also it's super fast and it saves people a ton of money. Visit www.structured meetings.com for more info. All right, back to the show.
Dr. Paul Peter Tak, President and CEO of Candel Therapeutics, sits down with Jonathan to discuss the company's sprint from positive Phase III results to commercial launch. They explore how Candel is redefining the...
In this episode, Jonathan sits down with Annel Duckels, who leads worldwide commercialization learning at Bristol Myers Squibb, to talk about modernizing pharma training through data and AI. Annel's unconventional path...
Pharma Sessions - ACTO Client Summit: Hallway Interviews At ACTO's 2026 client summit in Boston, we pulled some incredible minds out of the hallway for quick, candid conversations about where field excellence, AI, and...
What happens when you put blockchain underneath AI in healthcare? According to Archita Samant, Head of Data Strategy & Analytics for Global Vaccines at Merck - you finally solve the interoperability problem that's been...
What separates a good pharma sales rep from a great one? According to Jennifer Muszik, it's the ability to understand the question behind the question - the real need behind what a customer is asking. In this episode,...